Collegium Pharmaceutical (COLL) Total Current Liabilities (2014 - 2026)

Collegium Pharmaceutical's Total Current Liabilities history runs 13 years deep, the most recent figure standing at $435.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 10.63% year-over-year to $435.0 million in Q1 2026; TTM through Mar 2026 was $435.0 million, a 10.63% decrease from a year earlier, with the FY2025 full-year figure at $440.0 million, down 13.64% from the prior year.
• Total Current Liabilities retreated to $435.0 million in Q1 2026 per COLL's latest filing, from $440.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $509.5 million in Q4 2024 and bottomed at $373.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $446.4 million (2024), against an average of $444.9 million.
• Across the five-year window, Total Current Liabilities jumped 82.99% in 2022 and decreased 13.64% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $433.7 million in 2022, then gained by 5.58% to $457.9 million in 2023, then climbed by 11.27% to $509.5 million in 2024, then dropped by 13.64% to $440.0 million in 2025, then fell by 1.15% to $435.0 million in 2026.
• Per Business Quant, the three latest COLL Total Current Liabilities figures stand at $435.0 million (Q1 2026), $440.0 million (Q4 2025), and $452.9 million (Q3 2025).